Indivior Pharmaceuticals annual depreciation and amortization
2021
2022
2023
2024
2025
Indivior Pharmaceuticals Depreciation & Amortization Growth & History (INDV)
Indivior Pharmaceuticals's depreciation and amortization was $10.0M for fiscal 2025.
View full Indivior Pharmaceuticals company overviewIndivior Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $10.0M | −$6.0M | −37.50% |
| 2024 | 2024-12-31 | $16.0M | $1.0M | +6.67% |
| 2023 | 2023-12-31 | $15.0M | −$1.0M | −6.25% |
| 2022 | 2022-12-31 | $16.0M | $1.0M | +6.67% |
| 2021 | 2021-12-31 | $15.0M | — | — |
Indivior Pharmaceuticals quarterly depreciation and amortization
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.0M | $0 | 0.00% |
| Q1 2026 | 2026-03-31 | $2.0M | −$1.0M | −33.33% |
| Q4 2025 | 2025-12-31 | $5.0M | — | — |
| Q3 2025 | 2025-09-30 | $3.0M | −$1.0M | −25.00% |
| Q2 2025 | 2025-06-30 | $2.0M | $0 | 0.00% |
| Q1 2025 | 2025-03-31 | $3.0M | −$2.0M | −40.00% |
| Q3 2024 | 2024-09-30 | $4.0M | — | — |
| Q2 2024 | 2024-06-30 | $2.0M | — | — |
| Q1 2024 | 2024-03-31 | $5.0M | — | — |
Indivior Pharmaceuticals depreciation and amortization trends
Between the periods ended 2021-12-31 and 2025-12-31, Indivior Pharmaceuticals's depreciation and amortization decreased from $15.0M to $10.0M, a change of −$5.0M. The latest reported quarter, Q2 2026, shows $2.0M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Indivior Pharmaceuticals source filings ↗